Declan F. Doherty
Research Subjects
Declan F. Doherty has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Clifford C. Taggart
Airway Innate Immunity Group (AiiR), School of Medicine, Dentistry and Biomedical Sciences, Wellcome‐Wolfson Institute for Experimental Medicine Queen's University Belfast Belfast UK
2 shared publications - Ryan Brown
Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom
2 shared publications - Sinéad Weldon
Airway Innate Immunity Research Group
2 shared publications Anna Krasnodembskaya
Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, United Kingdom
1 shared publication- Claire Houston
Airway Innate Immunity Research (AiiR) group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, UK
1 shared publication Clifford C. Taggart
Airway Innate Immunity Research Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult βENaC‐Tg Mice
Background. Elevated levels of the cysteine protease cathepsin S (CatS) are associated with chronic mucoobstructive lung diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). We have previously demonstrated that prophylactic treatment with a CatS inhibitor from birth reduces inflammation, mucus plugging, and lung tissue damage in juvenile β‐epithelial Na+ channel‐overexpressing transgenic (βENaC‐Tg) mice with chronic inflammatory mucoobstructive lung disease. In this study, we build upon this work to examine the effects of therapeutic intervention with a CatS inhibitor in adult βENaC‐Tg mice with established disease. Methods. βENaC‐Tg mice and wild‐type (WT) littermates were treated with a CatS inhibitor from 4 to 6 weeks of age, and CatS-/-βENaC‐Tg mice were analysed at 6 weeks of age. Bronchoalveolar lavage (BAL) fluid inflammatory cell counts were quantified, and lung tissue destruction and mucus obstruction were analysed histologically. Results. At 6 weeks of age, βENaC‐Tg mice developed significant airway inflammation, lung tissue damage, and mucus plugging when compared to WT mice. CatS-/-βENaC‐Tg mice and βENaC‐Tg mice receiving inhibitor had significantly reduced airway mononuclear and polymorphonuclear (PMN) cell counts as well as mucus plugging. However, in contrast to CatS-/-βENaC‐Tg mice, therapeutic inhibition of CatS in βENaC‐Tg mice had no effect on established emphysema‐like lung tissue damage. Conclusions. These results suggest that while early CatS targeting may be required to prevent the onset and progression of lung tissue damage, therapeutic CatS targeting effectively inhibited airway inflammation and mucus obstruction. These results indicate the important role CatS may play in the pathogenesis and progression of mucoobstructive lung disease.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessTherapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult βENaC‐Tg Mice
Background. Elevated levels of the cysteine protease cathepsin S (CatS) are associated with chronic mucoobstructive lung diseases such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). We have previously demonstrated that prophylactic treatment with a CatS inhibitor from birth reduces inflammation, mucus plugging, and lung tissue damage in juvenile β‐epithelial Na+ channel‐overexpressing transgenic (βENaC‐Tg) mice with chronic inflammatory mucoobstructive lung disease. In this study, we build upon this work to examine the effects of therapeutic intervention with a CatS inhibitor in adult βENaC‐Tg mice with established disease. Methods. βENaC‐Tg mice and wild‐type (WT) littermates were treated with a CatS inhibitor from 4 to 6 weeks of age, and CatS-/-βENaC‐Tg mice were analysed at 6 weeks of age. Bronchoalveolar lavage (BAL) fluid inflammatory cell counts were quantified, and lung tissue destruction and mucus obstruction were analysed histologically. Results. At 6 weeks of age, βENaC‐Tg mice developed significant airway inflammation, lung tissue damage, and mucus plugging when compared to WT mice. CatS-/-βENaC‐Tg mice and βENaC‐Tg mice receiving inhibitor had significantly reduced airway mononuclear and polymorphonuclear (PMN) cell counts as well as mucus plugging. However, in contrast to CatS-/-βENaC‐Tg mice, therapeutic inhibition of CatS in βENaC‐Tg mice had no effect on established emphysema‐like lung tissue damage. Conclusions. These results suggest that while early CatS targeting may be required to prevent the onset and progression of lung tissue damage, therapeutic CatS targeting effectively inhibited airway inflammation and mucus obstruction. These results indicate the important role CatS may play in the pathogenesis and progression of mucoobstructive lung disease.
- Open Access
- 2 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 6379
Airway Inflammation and Host Responses in the Era of CFTR Modulators
The arrival of cystic fibrosis transmembrane conductance regulator (CFTR) modulators as a new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in disease management, as these small molecules directly target the upstream underlying protein defect. Further advancements in the development and scope of these genotype-specific therapies have been transformative for an increasing number of people with CF (PWCF). Despite clear improvements in CFTR function and clinical endpoints such as lung function, body mass index (BMI), and frequency of pulmonary exacerbations, current evidence suggests that CFTR modulators do not prevent continued decline in lung function, halt disease progression, or ameliorate pathogenic organisms in those with established lung disease. Furthermore, it remains unknown whether their restorative effects extend to dysfunctional CFTR expressed in phagocytes and other immune cells, which could modulate airway inflammation. In this review, we explore the effects of CFTR modulators on airway inflammation, infection, and their influence on the impaired pulmonary host defences associated with CF lung disease. We also consider the role of inflammation-directed therapies in light of the widespread clinical use of CFTR modulators and identify key areas for future research.
- 2 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 6379
Open AccessAirway Inflammation and Host Responses in the Era of CFTR Modulators
The arrival of cystic fibrosis transmembrane conductance regulator (CFTR) modulators as a new class of treatment for cystic fibrosis (CF) in 2012 represented a pivotal advance in disease management, as these small molecules directly target the upstream underlying protein defect. Further advancements in the development and scope of these genotype-specific therapies have been transformative for an increasing number of people with CF (PWCF). Despite clear improvements in CFTR function and clinical endpoints such as lung function, body mass index (BMI), and frequency of pulmonary exacerbations, current evidence suggests that CFTR modulators do not prevent continued decline in lung function, halt disease progression, or ameliorate pathogenic organisms in those with established lung disease. Furthermore, it remains unknown whether their restorative effects extend to dysfunctional CFTR expressed in phagocytes and other immune cells, which could modulate airway inflammation. In this review, we explore the effects of CFTR modulators on airway inflammation, infection, and their influence on the impaired pulmonary host defences associated with CF lung disease. We also consider the role of inflammation-directed therapies in light of the widespread clinical use of CFTR modulators and identify key areas for future research.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA3855
Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease
Mesenchymal stem cells (MSCs) are multipotent stromal cells that have been investigated in a number of lung diseases due to their immunomodulatory and reparative potential. In this study, we investigated whether MSC administration could reduce inflammation and tissue damage in the lungs of transgenic mice (scnn1b-Tg) overexpressing the β-subunit of the epithelial Na(+) channel (β-ENaC). At 8 weeks of age, the lungs of scnn1b-Tg mice are characterised by chronic lung inflammation, structural tissue damage and a reduction in lung function. To test whether MSC therapy could alter this phenotype, we administered PBS (vehicle control) or MSC cells (5 x 105 cells in 100 μl PBS) through tail vein injection at 4 and 6 weeks of age, with the endpoint at 8 weeks. Broncholaveolar lavage fluid analysis revealed that MSC administration significantly reduced infiltration of inflammatory cells into the lungs as total cell counts, monocytic cells and neutrophil counts were significantly decreased. Tissue analysis revealed that the mean linear intercept (MLI) and destructive index (DI), both markers of emphysema, were significantly improved in MSC treated mice. These findings were confirmed using lung function analysis on the SciReq Flexivent, which revealed that lung damage was significantly reduced after MSC therapy. In addition, analysis of gene expression profiles from macrophages extracted from MSC treated mice revealed a number of potential mechanisms of action, which are currently under investigation. These data suggest that MSC therapy can reduce inflammation and damage and that MSCs may provide an effective tool in the treatment of chronic inflammatory lung disease.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA3855
Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease
Mesenchymal stem cells (MSCs) are multipotent stromal cells that have been investigated in a number of lung diseases due to their immunomodulatory and reparative potential. In this study, we investigated whether MSC administration could reduce inflammation and tissue damage in the lungs of transgenic mice (scnn1b-Tg) overexpressing the β-subunit of the epithelial Na(+) channel (β-ENaC). At 8 weeks of age, the lungs of scnn1b-Tg mice are characterised by chronic lung inflammation, structural tissue damage and a reduction in lung function. To test whether MSC therapy could alter this phenotype, we administered PBS (vehicle control) or MSC cells (5 x 105 cells in 100 μl PBS) through tail vein injection at 4 and 6 weeks of age, with the endpoint at 8 weeks. Broncholaveolar lavage fluid analysis revealed that MSC administration significantly reduced infiltration of inflammatory cells into the lungs as total cell counts, monocytic cells and neutrophil counts were significantly decreased. Tissue analysis revealed that the mean linear intercept (MLI) and destructive index (DI), both markers of emphysema, were significantly improved in MSC treated mice. These findings were confirmed using lung function analysis on the SciReq Flexivent, which revealed that lung damage was significantly reduced after MSC therapy. In addition, analysis of gene expression profiles from macrophages extracted from MSC treated mice revealed a number of potential mechanisms of action, which are currently under investigation. These data suggest that MSC therapy can reduce inflammation and damage and that MSCs may provide an effective tool in the treatment of chronic inflammatory lung disease.